Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)

OBJECTIVES: To investigate the efficacy and safety of ixekizumab for up to 52 weeks in two phase 3 studies of patients with active radiographic axial spondyloarthritis (r-axSpA) who were biological disease-modifying antirheumatic drug (bDMARD)-naive (COAST-V) or tumour necrosis factor inhibitor (TNF...

Descripción completa

Detalles Bibliográficos
Autores principales: Dougados, Maxime, Wei, James Cheng-Chung, Landewé, Robert, Sieper, Joachim, Baraliakos, Xenofon, Van den Bosch, Filip, Maksymowych, Walter P, Ermann, Joerg, Walsh, Jessica A, Tomita, Tetsuya, Deodhar, Atul, van der Heijde, Désirée, Li, Xiaoqi, Zhao, Fangyi, Bertram, Clinton C, Gallo, Gaia, Carlier, Hilde, Gensler, Lianne S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Spondyloarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7025731/
https://www.ncbi.nlm.nih.gov/pubmed/31685553
http://dx.doi.org/10.1136/annrheumdis-2019-216118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7025731/
https://www.ncbi.nlm.nih.gov/pubmed/31685553
http://dx.doi.org/10.1136/annrheumdis-2019-216118

Ejemplares similares